ping an-杏耀平台代理注册

shenzhen, [september 29] c&o today announces the launch of its first next-generation proton pump inhibitor, rabeprazole sodium for injection (aobo ping®), in china. aubergine® is a self-developed product of c&o.

peptic ulcers are a globally prevalent disease with a high incidence of about 10%. a high percentage of patients with bleeding peptic ulcers, 43.4%, are at high risk of rebleeding. the launch of rabeprazole sodium for injection (aobo ping®) provides a new treatment option for patients with bleeding peptic ulcers and for healthcare providers treating peptic ulcers, meeting a growing market demand.

proton pump inhibitors (ppis) act to suppress gastric acid secretion by blocking the final stage of gastric acid secretion. aobo ping® developed by c&o, a second-generation proton pump inhibitor, is the first new drug to be marketed in china. the new drug product offers a new option for the treatment of patients with non-oral bleeding gastric ulcers and duodenal ulcers. compared with other injectable proton pump inhibitors, aobo ping® is characterized by faster onset of acid suppression and longer lasting potency; because rabeprazole is less susceptible to metabolism by cyp450 drug metabolizing enzymes, aobo ping® also has the advantages of small individual differences in efficacy and fewer drug interactions..

as a listed pharmaceutical company integrating r&d, production and sales of new drugs, c&o is committed to creating more drugs with better efficacy for patients and making great contributions to saving patients’ lives, and improving their health and human health.